These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8477573)

  • 1. Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.
    Murray PR; Jones RN; Allen SD; Erwin ME; Fuchs PC; Gerlach EH
    Diagn Microbiol Infect Dis; 1993; 16(3):191-203. PubMed ID: 8477573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Jun; 6(2 Suppl):92-3. PubMed ID: 3509542
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro activity of ceftazidime: comparison with other beta-lactam antibiotics.
    Vanhoof R; Gordts B; Coignau H; Stas G; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():63-6. PubMed ID: 19802970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
    Murray PR; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative in vitro activity ampicillin, cefoperazone, their combinations with sulbactam, as well as that of other antibiotics against aerobic gram-negative microorganisms].
    Sidorenko SV; Rezvan SP; Speranskaia ON; Krotova LA; Tikhonova AS; Strachunskiĭ LS; Navashin SM; Kuleshov SE; Budanov SV; Ansolis LE
    Antibiot Khimioter; 1994 Nov; 39(11):10-20. PubMed ID: 7733770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children.
    Citron DM; Goldstein EJ; Kenner MA; Burnham LB; Inderlied CB
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S356-60. PubMed ID: 7548597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G; Johnston J; Young LS; Martin WJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.
    Johnson CC
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S371-6. PubMed ID: 8324150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates.
    Ravizzola G; Pinsi G; Gonzales R; Colombrita D; Pirali F; Turano A
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1053-61. PubMed ID: 2620673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L; Devos J; Romond C
    Int J Clin Pharmacol Res; 1987; 7(1):39-43. PubMed ID: 3473047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of anaerobic bacteria in Bulgaria.
    Marina M; Ivanova M; Kantardjiev T
    Anaerobe; 2009 Aug; 15(4):127-32. PubMed ID: 19292999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of imipenem and 15 other antimicrobial agents against clinically important aerobic and anaerobic bacteria.
    Goldstein EJ; Citron DM
    Clin Ther; 1988; 10(5):487-515. PubMed ID: 2856592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of obligate anaerobes in infections in hospitalized patients and therapeutic options].
    Wróblewska M; Rokosz A; Sawicka-Grzelak A; Kot K; Luczak M
    Med Dosw Mikrobiol; 2005; 57(2):199-208. PubMed ID: 16134392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Mar; 32(3):403-6. PubMed ID: 3364960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
    Bujdáková H; Kallová J; Lausová A; Kettner M
    Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.